** Shares of drug developer CervoMed CRVO.O rise 58.7% to $14.25 premarket
** Co says its experimental drug, neflamapimod, significantly slowed disease progression in patients with dementia with Lewy bodies, the second most common form of dementia, based on 32-week extension data from its mid-stage trial
** The extension data come after a setback last December, when the drug failed to meet primary and secondary goals in the same trial, dragging its shares by 79%
** Patients who took neflamapimod showed a 54% lower risk of their disease getting worse compared to those who did not take the drug, co says
** Neflamapimod also reduced blood markers that indicate brain cell damage
** CRVO plans to meet with FDA in Q4 2025 to discuss late-stage trials
** As of last close, stock
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。